This study explores the effects of a drug called **mifomelatide** (TCMCB07) on patients with newly diagnosed colorectal cancer (CRC) or pancreatic ductal adenocarcinoma (PDAC) who are getting chemotherapy. Double-blind means neither the patient nor the doctor knows who is getting the actual drug or a placebo (a dummy treatment). **Randomized** means patients are randomly assigned to different groups, ensuring fairness. The aim is to see if different doses of mifomelatide help maintain body weight and muscle. Patients can join an optional Open Label Extension (OLE) after the main study to receive mifomelatide for longer and check for long-term effects.

• The main study lasts 12 weeks, with daily injections.
• Participants may join an extra 26-week study phase.
• Must be comfortable with or have help for daily self-injections.